213 related articles for article (PubMed ID: 36463731)
1. Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics.
Schipper LJ; Samsom KG; Snaebjornsson P; Battaglia T; Bosch LJW; Lalezari F; Priestley P; Shale C; van den Broek AJ; Jacobs N; Roepman P; van der Hoeven JJM; Steeghs N; Vollebergh MA; Marchetti S; Cuppen E; Meijer GA; Voest EE; Monkhorst K
ESMO Open; 2022 Dec; 7(6):100611. PubMed ID: 36463731
[TBL] [Abstract][Full Text] [Related]
2. CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence.
Zhao Y; Pan Z; Namburi S; Pattison A; Posner A; Balachander S; Paisie CA; Reddi HV; Rueter J; Gill AJ; Fox S; Raghav KPS; Flynn WF; Tothill RW; Li S; Karuturi RKM; George J
EBioMedicine; 2020 Nov; 61():103030. PubMed ID: 33039710
[TBL] [Abstract][Full Text] [Related]
3. Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE).
Samsom KG; Bosch LJW; Schipper LJ; Roepman P; de Bruijn E; Hoes LR; Riethorst I; Schoenmaker L; van der Kolk LE; Retèl VP; Frederix GWJ; Buffart TE; van der Hoeven JJM; Voest EE; Cuppen E; Monkhorst K; Meijer GA
BMC Med Genomics; 2020 Nov; 13(1):169. PubMed ID: 33167975
[TBL] [Abstract][Full Text] [Related]
4. Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary.
Posner A; Sivakumaran T; Pattison A; Etemadmoghadam D; Thio N; Wood C; Fisher K; Webb S; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Fellowes A; Fox SB; Hicks RJ; Schofield P; Bowtell D; Prall OWJ; Tothill RW; Mileshkin L
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36720497
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of whole-genome sequencing-based tumor diagnostics in routine pathology practice.
Samsom KG; Schipper LJ; Roepman P; Bosch LJ; Lalezari F; Klompenhouwer EG; de Langen AJ; Buffart TE; Riethorst I; Schoenmaker L; Schout D; van der Noort V; van den Berg JG; de Bruijn E; van der Hoeven JJ; van Snellenberg H; van der Kolk LE; Cuppen E; Voest EE; Meijer GA; Monkhorst K
J Pathol; 2022 Oct; 258(2):179-188. PubMed ID: 35792649
[TBL] [Abstract][Full Text] [Related]
6. [Whole genome sequencing to find the primary tumour in cancer of unknown primary origin].
van der Hoeven JJM; Monkhorst K; van de Wouw AJ; Roepman P
Ned Tijdschr Geneeskd; 2023 Sep; 167():. PubMed ID: 37823879
[TBL] [Abstract][Full Text] [Related]
7. Identification of Tissue of Origin and Guided Therapeutic Applications in Cancers of Unknown Primary Using Deep Learning and RNA Sequencing (TransCUPtomics).
Vibert J; Pierron G; Benoist C; Gruel N; Guillemot D; Vincent-Salomon A; Le Tourneau C; Livartowski A; Mariani O; Baulande S; Bidard FC; Delattre O; Waterfall JJ; Watson S
J Mol Diagn; 2021 Oct; 23(10):1380-1392. PubMed ID: 34325056
[TBL] [Abstract][Full Text] [Related]
8. TOD-CUP: a gene expression rank-based majority vote algorithm for tissue origin diagnosis of cancers of unknown primary.
Shen Y; Chu Q; Yin X; He Y; Bai P; Wang Y; Fang W; Timko MP; Fan L; Jiang W
Brief Bioinform; 2021 Mar; 22(2):2106-2118. PubMed ID: 32266390
[TBL] [Abstract][Full Text] [Related]
9. The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary
Dermawan JK; Rubin BP
Semin Diagn Pathol; 2021 Nov; 38(6):193-198. PubMed ID: 33309276
[TBL] [Abstract][Full Text] [Related]
10. Implementation of a novel microarray-based diagnostic test for cancer of unknown primary.
van Laar RK; Ma XJ; de Jong D; Wehkamp D; Floore AN; Warmoes MO; Simon I; Wang W; Erlander M; van't Veer LJ; Glas AM
Int J Cancer; 2009 Sep; 125(6):1390-7. PubMed ID: 19536816
[TBL] [Abstract][Full Text] [Related]
11. Cancer of Unknown Primary origin in the genomic era: Elucidating the dark box of cancer.
Economopoulou P; Mountzios G; Pavlidis N; Pentheroudakis G
Cancer Treat Rev; 2015 Jul; 41(7):598-604. PubMed ID: 26033502
[TBL] [Abstract][Full Text] [Related]
12. A molecular approach integrating genomic and DNA methylation profiling for tissue of origin identification in lung-specific cancer of unknown primary.
Chen K; Zhang F; Yu X; Huang Z; Gong L; Xu Y; Li H; Yu S; Fan Y
J Transl Med; 2022 Apr; 20(1):158. PubMed ID: 35382836
[TBL] [Abstract][Full Text] [Related]
13. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
Hainsworth JD; Rubin MS; Spigel DR; Boccia RV; Raby S; Quinn R; Greco FA
J Clin Oncol; 2013 Jan; 31(2):217-23. PubMed ID: 23032625
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Targeted Next-Generation Sequencing for the Management of Patients Diagnosed with a Cancer of Unknown Primary.
Fusco MJ; Knepper TC; Balliu J; Del Cueto A; Laborde JM; Hooda SM; Brohl AS; Bui MM; Hicks JK
Oncologist; 2022 Feb; 27(1):e9-e17. PubMed ID: 35305098
[TBL] [Abstract][Full Text] [Related]
15. Six-year experience of Australia's first dedicated cancer of unknown primary clinic.
van Mourik A; Tonkin-Hill G; O'Farrell J; Waller S; Tan L; Tothill RW; Bowtell D; Fox S; Fellowes A; Fedele C; Schofield P; Sivakumaran T; Wong HL; Mileshkin L
Br J Cancer; 2023 Aug; 129(2):301-308. PubMed ID: 37225894
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.
Hainsworth JD; Greco FA
Virchows Arch; 2014 Apr; 464(4):393-402. PubMed ID: 24487792
[TBL] [Abstract][Full Text] [Related]
17. Genetic characterisation of molecular targets in carcinoma of unknown primary.
Clynick B; Dessauvagie B; Sterrett G; Harvey NT; Allcock RJN; Saunders C; Erber W; Meehan K
J Transl Med; 2018 Jul; 16(1):185. PubMed ID: 29973234
[TBL] [Abstract][Full Text] [Related]
18. A Review on Cancer of Unknown Primary Origin: The Role of Molecular Biomarkers in the Identification of Unknown Primary Origin.
Yan N; Zhang Y; Guo X; Yuan D; Tian G; Yang J
Methods Mol Biol; 2020; 2204():109-119. PubMed ID: 32710319
[TBL] [Abstract][Full Text] [Related]
19. Overview of various techniques/platforms with critical evaluation of each.
Agwa E; Ma PC
Curr Treat Options Oncol; 2013 Dec; 14(4):623-33. PubMed ID: 24243164
[TBL] [Abstract][Full Text] [Related]
20. Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.
Hayashi H; Takiguchi Y; Minami H; Akiyoshi K; Segawa Y; Ueda H; Iwamoto Y; Kondoh C; Matsumoto K; Takahashi S; Yasui H; Sawa T; Onozawa Y; Chiba Y; Togashi Y; Fujita Y; Sakai K; Tomida S; Nishio K; Nakagawa K
JAMA Oncol; 2020 Dec; 6(12):1931-1938. PubMed ID: 33057591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]